"Sitagliptin Phosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazine-derived DIPEPTIDYL-PEPTIDASE IV INHIBITOR and HYPOGLYCEMIC AGENT that increases the levels of the INCRETIN hormones GLUCAGON-LIKE PEPTIDE-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It is used in the treatment of TYPE 2 DIABETES.
| Descriptor ID |
D000068900
|
| MeSH Number(s) |
D03.383.129.799.725 D03.383.679.875
|
| Concept/Terms |
Sitagliptin Phosphate- Sitagliptin Phosphate
- Phosphate, Sitagliptin
- Sitagliptin Phosphate Monohydrate
- Monohydrate, Sitagliptin Phosphate
- Phosphate Monohydrate, Sitagliptin
- Sitagliptin Monophosphate Monohydrate
- Monohydrate, Sitagliptin Monophosphate
- Monophosphate Monohydrate, Sitagliptin
MK 0431- MK 0431
- 0431, MK
- MK0431
- MK-0431
Sitagliptin- Sitagliptin
- 4-Oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
|
Below are MeSH descriptors whose meaning is more general than "Sitagliptin Phosphate".
Below are MeSH descriptors whose meaning is more specific than "Sitagliptin Phosphate".
This graph shows the total number of publications written about "Sitagliptin Phosphate" by people in this website by year, and whether "Sitagliptin Phosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sitagliptin Phosphate" by people in Profiles.
-
Impact of Insulin Sensitivity and ?-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy. Diabetes Care. 2024 Apr 01; 47(4):571-579.
-
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022 09 22; 387(12):1063-1074.
-
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension. 2022 04; 79(4):827-835.
-
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016. Am J Cardiol. 2021 08 01; 152:168.
-
Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model. Int J Mol Sci. 2018 Oct 18; 19(10).
-
Incretin Therapies Do Not Expand ?-Cell Mass or Alter Pancreatic Histology in Young Male Mice. Endocrinology. 2017 06 01; 158(6):1701-1714.
-
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obes Metab. 2013 Aug; 15(8):760-6.
-
Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther. 2013 Mar; 35(3):273-285.e7.
-
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012 Oct; 35(10):1986-93.
-
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011 Apr; 65(4):397-407.